Bayer Lands First-in-Class Stroke Drug Approval as Guidance Rises and Analysts Diverge
Published on 11/16/2026 at 11:50 | Editorial boerse-global.deBayer's pharmaceutical unit has secured a regulatory first in the US, winning FDA approval for its factor XIa inhibitor Asundexian — marketed as Sunharbo — just as the company sharpens its full-year forecasts and faces a split verdict from the analyst community.
The agency cleared Sunharbo to reduce the risk of further strokes in certain adults, specifically for use alongside antiplatelet therapy. The label covers patients who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, confining the indication to the patient groups and combination regimen the FDA specified. Bayer described the compound as the world's first approved factor XIa inhibitor.
The green light, disclosed by the company on 10 November, arrives at a sensitive moment for the group's pharma division, which is hunting for replacements as revenue from its flagship Xarelto treatment declines. Handelsblatt framed the US authorization as strategically significant for that reason, casting the drug as a candidate to offset the erosion in Xarelto sales. The decision also lent fresh momentum to the shares, according to dpa-AFX.
Forecasts Raised Ahead of 2027 Guidance
Bayer had already lifted its 2026 outlook for the pharma division's margin on 3 November, alongside higher expectations for group EBITDA before special items and free cash flow. The Leverkusen-based company also projected a lower net financial debt figure. Third-quarter 2026 group revenue reached EUR 10.1 billion, with EBITDA before special items of EUR 1.62 billion. Management intends to set out its 2027 guidance at the annual results press conference.
Should investors sell immediately? Or is it worth buying Bayer?
China added a second approval to the week's tally: on 4 November, Sevabertinib was cleared there as a first-line treatment for patients with advanced HER2-mutated non-small cell lung cancer.
Litigation Win Cuts One Strand of Risk
On the legal front, a Missouri jury dismissed claims brought by three plaintiffs against Bayer subsidiary Monsanto on 9 November, Reuters reported. The verdict applies solely to that individual case and does not determine the pending settlement covering the broader litigation.
A Street Divided on What the Approval Is Worth
Deutsche Bank Research raised its price target to EUR 65 from EUR 60 on 10 November while reaffirming its buy rating. Analyst Virginie Boucher-Ferte also lifted her earnings estimates for 2027 and 2028, dpa-AFX noted. Jefferies stayed on the sidelines the same day, keeping a hold rating and a EUR 48.50 target. Analyst Michael Leuchten read the Asundexian approval — which came in as expected — as a substantial reduction of risk for Bayer's pharma pipeline.
Bayer at a turning point? This analysis reveals what investors need to know now.
The shares closed Friday at EUR 56.66, up 0.2% on the day, after the US approval was announced earlier in the week.
Ad
Bayer Stock: New Analysis - 16 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
